Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2–17-year-old children with asplenia or splenic dysfunction: A phase 3 study
Under a Creative Commons license
open access
Keywords
Pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Immunogenicity
Safety
Asplenia
Splenic dysfunction
Abbreviations
AE
adverse event
ATP
according-to-protocol
CI
confidence interval
ELISA
enzyme-linked immunosorbent assay
22F-ELISA
enzyme-linked immunosorbent assay with serotype 22F polysaccharide adsorption
GMC
geometric mean concentration
GMT
geometric mean titer
IgG
immunoglobulin G
EL.U
ELISA units
LARs
legally acceptable representatives
NIP
national immunization program
OPA
opsonophagocytic activity
PCV
pneumococcal conjugate vaccine
PHiD-CV
pneumococcal non-typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine
PPSV23
23-valent pneumococcal plain polysaccharide vaccine
SCD
sickle cell disease
SAE
serious adverse event
TVC
total vaccinated cohort
ST
serotype
SD
standard deviation
Cited by (0)
© 2017 GlaxoSmithKline SA. Published by Elsevier Ltd.